Cancer Terminator Viruses and Approaches for Enhancing Therapeutic Outcomes

Advances in Cancer Research

Volumn 115, Issue , 2012, Pages 1-38

  Das, Swadesh K ^a   Sarkar, Siddik ^a   Dash, Rupesh ^a   Dent, Paul ^a,b   Wang, Xiang Yang ^a,b   Sarkar, Devanand ^a,b   Fisher, Paul B ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Adenovirus (Ad); Cancer terminator virus; Interferon ; Melanoma differentiation associated gene 7 interleukin 24; Microbubbles; Progression elevated gene 3

Indexed keywords

ADENOVIRUS VECTOR; BETA INTERFERON; CANCER TERMINATOR VIRUS; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; HERPESVIRUS VECTOR; INTERLEUKIN 10; INTERLEUKIN 24; LONTUCIREV; MITOGEN ACTIVATED PROTEIN KINASE P38; ONCOLYTIC VIRUS; PARVOVIRUS VECTOR; REACTIVE OXYGEN METABOLITE; RETINOBLASTOMA PROTEIN; RETROVIRUS VECTOR; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; VIRUS RNA; GAMMA INTERFERON; INTERLEUKIN DERIVATIVE; INTERLEUKIN-24;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOGENIC ACTIVITY; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOMAL LOCALIZATION; COLORECTAL CARCINOMA; DNA DAMAGE; ENDOPLASMIC RETICULUM STRESS; ENHANCER REGION; GENE EXPRESSION; GENE FUNCTION; GENETIC ENGINEERING; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; INTERFERON GAMMA RELEASE ASSAY; KIDNEY CARCINOMA; METASTASIS; MICROBUBBLE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; TRANSGENE; TUMOR REGRESSION; ULTRASOUND TARGETED MICROBUBBLE DESTRUCTION; UNFOLDED PROTEIN RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRUS GENOME; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; BIOLOGICAL MODEL; GENE THERAPY; GENETICS; METABOLISM; METHODOLOGY; NEOPLASM; ONCOLOGY; REVIEW; VIROLOGY;

ADENOVIRIDAE; ANIMALS; GENETIC THERAPY; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; MEDICAL ONCOLOGY; MICROBUBBLES; MODELS, BIOLOGICAL; MODELS, GENETIC; NEOPLASM METASTASIS; NEOPLASMS; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TRANSGENES;

EID: 84866788367     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-398342-8.00001-X     Document Type: Chapter

References (153)

1. Alba R., Bosch A., Chillon M. Gutless adenovirus: Last-generation adenovirus for gene therapy. Gene Therapy 2005, 12(Suppl. 1):S18-S27.
2. Azab B., Dash R., Das S.K., Bhutia S.K., Shen X.N., Quinn B.A., et al. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. Journal of Cellular Physiology 2011, 227(5):2145-2153.
3. Babiss L.E., Zimmer S.G., Fisher P.B. Reversibility of progression of the transformed phenotype in Ad5-transformed rat embryo cells. Science 1985, 228(4703):1099-1101.
4. Banerjee N.S., Rivera A.A., Wang M., Chow L.T., Broker T.R., Curiel D.T., et al. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. Molecular Cancer Therapeutics 2004, 3(4):437-449.
5. Bardeesy N., DePinho R.A. Pancreatic cancer biology and genetics. Nature Reviews. Cancer 2002, 2(12):897-909.
6. Bhang H.E.C., Gabrielson K.L., Laterra J., Fisher P.B., Pomper M.G. Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nature Medicine 2011, 17(1):123-U302.
7. Bhutia S.K., Das S.K., Kegelman T.P., Azab B., Dash R., Su Z.Z., et al. mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. Journal of Cellular Physiology 2011, 227:1805-1813.
8. Bhutia S.K., Dash R., Das S.K., Azab B., Su Z.Z., Lee S.G., et al. Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Research 2010, 70(9):3667-3676.
9. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274(5286):373-376.
10. Borden E.C., Lotan R., Levens D., Young C.W., Waxman S. Differentiation therapy of cancer: Laboratory and clinical investigations. Cancer Research 1993, 53(17):4109-4115.
11. Cancer Figurs and Facts (2012). January 4, 2012. http://www.cancer.org.
12. Cao X., Wei R., Liu X., Zeng Y., Huang H., Ding M., et al. Cancer targeting gene-viro-therapy specific for liver cancer by alpha-fetoprotein-controlled oncolytic adenovirus expression of SOCS3 and IL-24. Acta Biochimica et Biophysica Sinica (Shanghai) 2011, 43(10):813-821.
13. Cascallo M., Capella G., Mazo A., Alemany R. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Research 2003, 63(17):5544-5550.
14. Caudell E.G., Mumm J.B., Poindexter N., Ekmekcioglu S., Mhashilkar A.M., Yang X.H., et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. The Journal of Immunology 2002, 168(12):6041-6046.
15. Chada S., Mhashilkar A.M., Liu Y., Nishikawa T., Bocangel D., Zheng M., et al. mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: Correlation with expression of bcl-2 family members. Cancer Gene Therapy 2006, 13(5):490-502.
16. Chada S., Sutton R.B., Ekmekcioglu S., Ellerhorst J., Mumm J.B., Leitner W.W., et al. MDA-7/IL-24 is a unique cytokine-Tumor suppressor in the IL-10 family. International Immunopharmacology 2004, 4(5):649-667.
17. Chen L., Chen D., Manome Y., Dong Y., Fine H.A., Kufe D.W. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. The Journal of Clinical Investigation 1995, 96(6):2775-2782.
18. Chen M.J., Green N.K., Reynolds G.M., Flavell J.R., Mautner V., Kerr D.J., et al. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Therapy 2004, 11(14):1126-1136.
19. Choi K.J., Kim J.H., Lee Y.S., Kim J., Suh B.S., Kim H., et al. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Therapy 2006, 13(13):1010-1020.
20. Colombel M., Symmans F., Gil S., O'Toole K.M., Chopin D., Benson M., et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. The American Journal of Pathology 1993, 143(2):390-400.
21. Cunningham C.C., Chada S., Merritt J.A., Tong A., Senzer N., Zhang Y., et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: A phase I study. Molecular Therapy 2005, 11(1):149-159.
22. Dash R., Azab B., Quinn B.A., Shen X., Wang X.Y., Das S.K., et al. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(21):8785-8790.
23. Dash R., Bhutia S.K., Azab B., Su Z.Z., Quinn B.A., Kegelmen T.P., et al. mda-7/IL-24: A unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine & Growth Factor Reviews 2010, 21(5):381-391.
24. Dash R., Dmitriev I., Su Z.Z., Bhutia S.K., Azab B., Vozhilla N., et al. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low CAR prostate cancer cells. Cancer Gene Therapy 2010, 17(7):447-456.
25. Dedieu J.F., Vigne E., Torrent C., Jullien C., Mahfouz I., Caillaud J.M., et al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. Journal of Virology 1997, 71(6):4626-4637.
26. DeWeese T.L., van der Poel H., Li S., Mikhak B., Drew R., Goemann M., et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Research 2001, 61(20):7464-7472.
27. Di Lorenzo G., De Placido S. Hormone refractory prostate cancer (HRPC): Present and future approaches of therapy. International Journal of Immunopathology and Pharmacology 2006, 19(1):11-34.
28. Donahue T.R., Reber H.A. Pancreatic surgery. Current Opinion in Gastroenterology 2010, 26(5):499-505.
29. Eager R., Harle L., Nemunaitis J. Ad-MDA-7; INGN 241: A review of preclinical and clinical experience. Expert Opinion on Biological Therapy 2008, 8(10):1633-1643.
30. Ellwood-Yen K., Graeber T.G., Wongvipat J., Iruela-Arispe M.L., Zhang J., Matusik R., et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003, 4(3):223-238.
31. Emdad L., Lebedeva I.V., Su Z.Z., Gupta P., Sauane M., Dash R., et al. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biology & Therapy 2009, 8(5):391-400.
32. Emdad L., Sarkar D., Su Z.Z., Boukerche H., Bar-Eli M., Fisher P.B. Progression elevated gene-3 (PEG-3) induces pleiotropic effects on tumor progression: Modulation of genomic stability and invasion. Journal of Cellular Physiology 2005, 202(1):135-146.
33. Enders J.F., Bell J.A., Dingle J.H., Francis T., Hilleman M.R., Huebner R.J., et al. Adenoviruses: Group name proposed for new respiratory-tract viruses. Science 1956, 124(3212):119-120.
34. Eulitt P.J., Park M.A., Hossein H., Cruikshanks N., Yang C., Dmitriev I.P., et al. Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad5/3 gene delivery. Cancer Biology & Therapy 2011, 10(12):1290-1305.
35. Fisher P.B. Is mda-7/IL-24 a " magic bullet" for cancer?. Cancer Research 2005, 65(22):10128-10138.
36. Fisher P.B., Bozzone J.H., Weinstein I.B. Tumor promoters and epidermal growth factor stimulate anchorage-independent growth of adenovirus-transformed rat embryo cells. Cell 1979, 18(3):695-705.
37. Fisher P.B., Gopalkrishnan R.V., Chada S., Ramesh R., Grimm E.A., Rosenfeld M.R., et al. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: From the laboratory into the clinic. Cancer Biology & Therapy 2003, 2(4 Suppl. 1):S23-S37.
38. Fisher P.B., Hermo H., Solowey W.E., Dietrich M.C., Edwalds G.M., Weinstein I.B., Langer J.A., Pestka S., Giacomini P., Kusama M., et al. Effect of recombinant human fibroblast interferon and mezerein on growth, differentiation, immune interferon binding and tumor associated antigen expression in human melanoma cells. Anticancer Res 1986, 6(4):765-774.
39. Fisher P.B., Prignoli D.R., Hermo H., Weinstein I.B., Pestka S. Effects of combined treatment with interferon and mezerein on melanogenesis and growth in human melanoma cells. Journal of Interferon Research 1985, 5(1):11-22.
40. Freytag S.O., Khil M., Stricker H., Peabody J., Menon M., DePeralta-Venturina M., et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Research 2002, 62(17):4968-4976.
41. Freytag S.O., Stricker H., Pegg J., Paielli D., Pradhan D.G., Peabody J., et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Research 2003, 63(21):7497-7506.
42. Fuerer C., Iggo R. Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Therapy 2002, 9(4):270-281.
43. Fueyo J., Gomez-Manzano C., Alemany R., Lee P.S., McDonnell T.J., Mitlianga P., et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000, 19(1):2-12.
44. Fujiwara T., Shirakawa Y., Kagawa S. Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer. Expert Review of Anticancer Therapy 2011, 11(4):525-532.
45. Fujiwara T., Urata Y., Tanaka N. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Current Cancer Drug Targets 2007, 7(2):191-201.
46. Fukazawa T., Matsuoka J., Yamatsuji T., Maeda Y., Durbin M.L., Naomoto Y. Adenovirus-mediated cancer gene therapy and virotherapy (Review). International Journal of Molecular Medicine 2010, 25(1):3-10.
47. Goldberg B.B., Liu J.B., Forsberg F. Ultrasound contrast agents: A review. Ultrasound in Medicine & Biology 1994, 20(4):319-333.
48. Gomez-Manzano C., Fueyo J., Kyritsis A.P., Steck P.A., Roth J.A., McDonnell T.J., et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Research 1996, 56(4):694-699.
49. Gopalkrishnan R.V., Sauane M., Fisher P.B. Cytokine and tumor cell apoptosis inducing activity of mda-7/IL-24. International Immunopharmacology 2004, 4(5):635-647.
50. Greco A., Di Benedetto A., Howard C.M., Kelly S., Nande R., Dementieva Y., et al. Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Molecular Therapy 2010, 18(2):295-306.
51. Gupta P., Emdad L., Lebedeva I.V., Sarkar D., Dent P., Curiel D.T., et al. mda-7/IL-24: Multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacology and Therapeutics 2006, 111(3):596-628.
52. Hall A.R., Dix B.R., O'Carroll S.J., Braithwaite A.W. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nature Medicine 1998, 4(9):1068-1072.
53. Hallenbeck P.L., Chang Y.N., Hay C., Golightly D., Stewart D., Lin J., et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Human Gene Therapy 1999, 10(10):1721-1733.
54. Hamed H.A., Yacoub A., Park M.A., Eulitt P.J., Dash R., Sarkar D., et al. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Molecular Therapy 2010, 18(6):1130-1142.
55. Haviv Y.S., Blackwell J.L., Kanerva A., Nagi P., Krasnykh V., Dmitriev I., et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Research 2002, 62(15):4273-4281.
56. Heise C., Hermiston T., Johnson L., Brooks G., Sampson-Johannes A., Williams A., et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nature Medicine 2000, 6(10):1134-1139.
57. Heise C., Kirn D.H. Replication-selective adenoviruses as oncolytic agents. The Journal of Clinical Investigation 2000, 105(7):847-851.
58. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., Kirn D.H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Medicine 1997, 3(6):639-645.
59. Heise C.C., Williams A.M., Xue S., Propst M., Kirn D.H. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Research 1999, 59(11):2623-2628.
60. Hoffmann D., Wildner O. Restriction of adenoviral replication to the transcriptional intersection of two different promoters for colorectal and pancreatic cancer treatment. Molecular Cancer Therapeutics 2006, 5(2):374-381.
61. Hollander M.C., Poola-Kella S., Fornace A.J. Gadd34 functional domains involved in growth suppression and apoptosis. Oncogene 2003, 22(25):3827-3832.
62. Howard C.M., Forsberg F., Minimo C., Liu J.B., Merton D.A., Claudio P.P. Ultrasound guided site specific gene delivery system using adenoviral vectors and commercial ultrasound contrast agents. Journal of Cellular Physiology 2006, 209(2):413-421.
63. Huang E.Y., Madireddi M.T., Gopalkrishnan R.V., Leszczyniecka M., Su Z., Lebedeva I.V., et al. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene 2001, 20(48):7051-7063.
64. Huang T.G., Savontaus M.J., Shinozaki K., Sauter B.V., Woo S.L. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Therapy 2003, 10(15):1241-1247.
65. Inoue S., Shanker M., Miyahara R., Gopalan B., Patel S., Oida Y., et al. MDA-7/IL-24-based cancer gene therapy: Translation from the laboratory to the clinic. Current Gene Therapy 2006, 6(1):73-91.
66. Irving J., Wang Z., Powell S., O'Sullivan C., Mok M., Murphy B., et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Therapy 2004, 11(3):174-185.
67. Jaffee E.M., Hruban R.H., Canto M., Kern S.E. Focus on pancreas cancer. Cancer Cell 2002, 2(1):25-28.
68. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 2010, 60(5):277-300.
69. Jiang H., Fisher P.B. Use of a sensitive and efficient subtraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells. Molecular and Cellular Differentiation 1993, 1(3):285-299.
70. Jiang H., Lin J.J., Su Z.Z., Goldstein N.I., Fisher P.B. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995, 11(12):2477-2486.
71. Jiang H., Shah S., Hilt D.C. Organization, sequence, and expression of the murine S100 beta gene. Transcriptional regulation by cell type-specific cis-acting regulatory elements. The Journal of Biological Chemistry 1993, 268(27):20502-20511.
72. Jiang H., Su Z.Z., Lin J.J., Goldstein N.I., Young C.S., Fisher P.B. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(17):9160-9165.
73. Johnson L., Shen A., Boyle L., Kunich J., Pandey K., Lemmon M., et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002, 1(4):325-337.
74. Kanai F., Shiratori Y., Yoshida Y., Wakimoto H., Hamada H., Kanegae Y., et al. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology 1996, 23(6):1359-1368.
75. Kanerva A., Mikheeva G.V., Krasnykh V., Coolidge C.J., Lam J.T., Mahasreshti P.J., et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clinical Cancer Research 2002, 8(1):275-280.
76. Kawakami Y., Li H., Lam J.T., Krasnykh V., Curiel D.T., Blackwell J.L. Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Research 2003, 63(6):1262-1269.
77. Kim J., Cho J.Y., Kim J.H., Jung K.C., Yun C.O. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Therapy 2002, 9(9):725-736.
78. Kim E., Kim J.H., Shin H.Y., Lee H., Yang J.M., Kim J., et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Human Gene Therapy 2003, 14(15):1415-1428.
79. Kim M., Zinn K.R., Barnett B.G., Sumerel L.A., Krasnykh V., Curiel D.T., et al. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. European Journal of Cancer 2002, 38(14):1917-1926.
80. Kirn D.H., McCormick F. Replicating viruses as selective cancer therapeutics. Molecular Medicine Today 1996, 2(12):519-527.
81. Krajewska M., Krajewski S., Epstein J.I., Shabaik A., Sauvageot J., Song K., et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. The American Journal of Pathology 1996, 148(5):1567-1576.
82. Krajewski S., Krajewska M., Shabaik A., Wang H.G., Irie S., Fong L., et al. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Research 1994, 54(21):5501-5507.
83. Krasnykh V.N., Mikheeva G.V., Douglas J.T., Curiel D.T. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. Journal of Virology 1996, 70(10):6839-6846.
84. Lanson N.A., Friedlander P.L., Schwarzenberger P., Kolls J.K., Wang G. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Research 2003, 63(22):7936-7941.
85. Larina I.V., Evers B.M., Ashitkov T.V., Bartels C., Larin K.V., Esenaliev R.O. Enhancement of drug delivery in tumors by using interaction of nanoparticles with ultrasound radiation. Technology in Cancer Research & Treatment 2005, 4(2):217-226.
86. Lawrie A., Brisken A.F., Francis S.E., Cumberland D.C., Crossman D.C., Newman C.M. Microbubble-enhanced ultrasound for vascular gene delivery. Gene Therapy 2000, 7(23):2023-2027.
87. Lebedeva I.V., Emdad L., Su Z.Z., Gupta P., Sauane M., Sarkar D., et al. mda-7/IL-24, novel anticancer cytokine: Focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). International Journal of Oncology 2007, 31(5):985-1007.
88. Lebedeva I.V., Sarkar D., Su Z.Z., Kitada S., Dent P., Stein C.A., et al. Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 2003, 22(54):8758-8773.
89. Lebedeva I.V., Su Z.Z., Sarkar D., Kitada S., Dent P., Waxman S., et al. Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. Cancer Research 2003, 63(23):8138-8144.
90. Lee B., Choi J., Kim J., Kim J.H., Joo C.H., Cho Y.K., et al. Oncolysis of human gastric cancers by an E1B 55 kDa-deleted YKL-1 adenovirus. Cancer Letters 2002, 185(2):225-233.
91. Li Y., Chen Y., Dilley J., Arroyo T., Ko D., Working P., et al. Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Molecular Cancer Therapeutics 2003, 2(10):1003-1009.
92. Liang J., Huang R.L., Huang Q., Peng Z., Zhang P.H., Wu Z.X. Adenovirus-mediated human interleukin 24 (MDA-7/IL-24) selectively suppresses proliferation and induces apoptosis in keloid fibroblasts. Annals of Plastic Surgery 2011, 66(6):660-666.
93. Mathis J.M., Stewart P.L., Zhu Z.B., Curiel D.T. Advanced generation adenoviral virotherapy agents embody enhanced potency based upon CAR-independent tropism. Clinical Cancer Research 2006, 12(9):2651-2656.
94. Miao J., Chen G.G., Chun S.Y., Yun J.P., Chak E.C., Ho R.L., et al. Adenovirus-mediated tBid overexpression results in therapeutic effects on p53-resistant hepatocellular carcinoma. International Journal of Cancer 2006, 119(8):1985-1993.
95. Nettelbeck D.M. Virotherapeutics: Conditionally replicative adenoviruses for viral oncolysis. Anti-Cancer Drugs 2003, 14(8):577-584.
96. Nettelbeck D.M., Rivera A.A., Balague C., Alemany R., Curiel D.T. Novel oncolytic adenoviruses targeted to melanoma: Specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Research 2002, 62(16):4663-4670.
97. Ng K.Y., Liu Y. Therapeutic ultrasound: Its application in drug delivery. Medicinal Research Reviews 2002, 22(2):204-223.
98. O'Shea C.C., Johnson L., Bagus B., Choi S., Nicholas C., Shen A., et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004, 6(6):611-623.
99. Park J.S., Qiao L., Su Z.Z., Hinman D., Willoughby K., McKinstry R., et al. PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells. Autophagy 2008, 4(4):513-515.
100. Pitt W.G., Husseini G.A., Staples B.J. Ultrasonic drug delivery-A general review. Expert Opinion on Drug Delivery 2004, 1(1):37-56.
101. Ramesh R., Mhashilkar A.M., Tanaka F., Saito Y., Branch C.D., Sieger K., et al. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Research 2003, 63(16):5105-5113.
102. Rein D.T., Breidenbach M., Kirby T.O., Han T., Siegal G.P., Bauerschmitz G.J., et al. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clinical Cancer Research 2005, 11(3):1327-1335.
103. Rivera A.A., Davydova J., Schierer S., Wang M., Krasnykh V., Yamamoto M., et al. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Therapy 2004, 11(23):1694-1702.
104. Rodriguez R., Schuur E.R., Lim H.Y., Henderson G.A., Simons J.W., Henderson D.R. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Research 1997, 57(13):2559-2563.
105. Roth J.A., Cristiano R.J. Gene therapy for cancer: What have we done and where are we going?. Journal of the National Cancer Institute 1997, 89(1):21-39.
106. Russo S., Butler J., Ove R., Blackstock A.W. Locally advanced pancreatic cancer: A review. Seminars in Oncology 2007, 34(4):327-334.
107. Sachs L. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia. Nature 1978, 274(5671):535-539.
108. Sachs L. Cell differentiation and bypassing of genetic defects in the suppression of malignancy. Cancer Research 1987, 47(8):1981-1986.
109. Sachs L. The control of growth and differentiation in normal and leukemic blood cells. Cancer 1990, 65(10):2196-2206.
110. Sarkar D., Lebedeva I.V., Gupta P., Emdad L., Sauane M., Dent P., et al. Melanoma differentiation associated gene-7 (mda-7)/IL-24: A 'magic bullet' for cancer therapy?. Expert Opinion on Biological Therapy 2007, 7(5):577-586.
111. Sarkar D., Su Z.Z., Fisher P.B. Unique conditionally replication competent bipartite adenoviruses-cancer terminator viruses (CTV): Efficacious reagents for cancer gene therapy. Cell Cycle 2006, 5(14):1531-1536.
112. Sarkar D., Su Z.Z., Lebedeva I.V., Sauane M., Gopalkrishnan R.V., Valerie K., et al. mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(15):10054-10059.
113. Sarkar D., Su Z.Z., Park E.S., Vozhilla N., Dent P., Curiel D.T., et al. A cancer terminator virus eradicates both primary and distant human melanomas. Cancer Gene Therapy 2008, 15(5):293-302.
114. Sarkar D., Su Z.Z., Vozhilla N., Park E.S., Gupta P., Fisher P.B. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(39):14034-14039.
115. Sarkar D., Su Z.Z., Vozhilla N., Park E.S., Randolph A., Valerie K., et al. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Research 2005, 65(19):9056-9063.
116. Sauane M., Gopalkrishnan R.V., Lebedeva I., Mei M.X., Sarkar D., Su Z.Z., et al. MDA-7/IL-24: Novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine & Growth Factor Reviews 2003, 14(1):35-51.
117. Sauane M., Lebedeva I.V., Su Z.Z., Choo H.T., Randolph A., Valerie K., et al. Melanoma differentiation associated gene-7/interleukin-24 promotes tumor cell-specific apoptosis through both secretory and nonsecretory pathways. Cancer Research 2004, 64(9):2988-2993.
118. Sauane M., Su Z.Z., Gupta P., Lebedeva I.V., Dent P., Sarkar D., et al. Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(28):9763-9768.
119. Smith A.E. Viral vectors in gene therapy. Annual Review of Microbiology 1995, 49:807-838.
120. Smith R.R., Huebner R.J., Rowe W.P., Schatten W.E., Thomas L.B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956, 9(6):1211-1218.
121. Staudt M.R., Depass A.L., Sarkar D., Fisher P.B. Model cell culture system for defining the molecular and biochemical events mediating terminal differentiation of human melanoma cells. Journal of Cellular Physiology 2009, 218(2):304-314.
122. Staudt M.R., Dittmer D.P. The Rta/Orf50 transactivator proteins of the gamma-herpesviridae. Current Topics in Microbiology and Immunology 2007, 312:71-100.
123. Sternberg C.N. Highlights of contemporary issues in the medical management of prostate cancer. Critical Reviews in Oncology/Hematology 2002, 43(2):105-121.
124. Su Z.Z., Emdad L., Sarkar D., Randolph A., Valerie K., Yacoub A., et al. Potential molecular mechanism for rodent tumorigenesis: Mutational generation of Progression Elevated Gene-3 (PEG-3). Oncogene 2005, 24(13):2247-2255.
125. Su Z., Emdad L., Sauane M., Lebedeva I.V., Sarkar D., Gupta P., et al. Unique aspects of mda-7/IL-24 antitumor bystander activity: Establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene 2005, 24(51):7552-7566.
126. Su Z.Z., Gopalkrishnan R.V., Narayan G., Dent P., Fisher P.B. Progression elevated gene-3, PEG-3, induces genomic instability in rodent and human tumor cells. Journal of Cellular Physiology 2002, 192(1):34-44.
127. Su Z.Z., Lebedeva I.V., Sarkar D., Gopalkrishnan R.V., Sauane M., Sigmon C., et al. Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene 2003, 22(8):1164-1180.
128. Su C., Peng L., Sham J., Wang X., Zhang Q., Chua D., et al. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Molecular Therapy 2006, 13(5):918-927.
129. Su Z.Z., Sarkar D., Emdad L., Duigou G.J., Young C.S., Ware J., et al. Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(4):1059-1064.
130. Su Z.Z., Shi Y., Fisher P.B. Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(17):9125-9130.
131. Su Z., Shi Y., Fisher P.B. Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells. Oncogene 2000, 19(30):3411-3421.
132. Su Z., Shi Y., Friedman R., Qiao L., McKinstry R., Hinman D., et al. PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells. Nucleic Acids Research 2001, 29(8):1661-1671.
133. Thomas C.E., Ehrhardt A., Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nature Reviews Genetics 2003, 4(5):346-358.
134. Tong A.W., Nemunaitis J., Su D., Zhang Y., Cunningham C., Senzer N., et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): Biologic outcome in advanced cancer patients. Molecular Therapy 2005, 11(1):160-172.
135. Tooze J. Molecular biology of tumor viruses (Part 2) 1980, Cold Spring Harbor Laboratory, New York.
136. Turnell A.S., Grand R.J., Gallimore P.H. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. Journal of Virology 1999, 73(3):2074-2083.
137. Van Houdt W.J., Haviv Y.S., Lu B., Wang M., Rivera A.A., Ulasov I.V., et al. The human survivin promoter: A novel transcriptional targeting strategy for treatment of glioma. Journal of Neurosurgery 2006, 104(4):583-592.
138. Volk A.L., Rivera A.A., Kanerva A., Bauerschmitz G., Dmitriev I., Nettelbeck D.M., et al. Enhanced adenovirus infection of melanoma cells by fiber-modification: Incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biology & Therapy 2003, 2(5):511-515.
139. Whyte P., Ruley H.E., Harlow E. Two regions of the adenovirus early region 1A proteins are required for transformation. Journal of Virology 1988, 62(1):257-265.
140. Wildner O., Blaese R.M., Morris J.C. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Research 1999, 59(2):410-413.
141. Wirth T., Zender L., Schulte B., Mundt B., Plentz R., Rudolph K.L., et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Research 2003, 63(12):3181-3188.
142. Wu Y.M., Zhang K.J., Yue X.T., Wang Y.Q., Yang Y., Li G.C., et al. Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24. Acta Pharmacologica Sinica 2009, 30(4):467-477.
143. Wu T.L., Zhou D. Viral delivery for gene therapy against cell movement in cancer. Advanced Drug Delivery Reviews 2011, 63(8):671-677.
144. Xiao L., Li X., Niu N., Qian J., Xie G., Wang Y. Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24. Molecular and Cellular Biochemistry 2010, 340(1-2):31-40.
145. Xue X.B., Xiao C.W., Zhang H., Lu A.G., Gao W., Zhou Z.Q., et al. Oncolytic adenovirus SG600-IL24 selectively kills hepatocellular carcinoma cell lines. World Journal of Gastroenterology 2010, 16(37):4677-4684.
146. Yamamoto M., Curiel D.T. Current issues and future directions of oncolytic adenoviruses. Molecular Therapy 2010, 18(2):243-250.
147. Yang B.X., Duan Y.J., Dong C.Y., Zhang F., Gao W.F., Cui X.Y., et al. Novel functions for mda-7/IL-24 and IL-24 delE5: Regulation of differentiation of acute myeloid leukemic cells. Molecular Cancer Therapeutics 2011, 10(4):615-625.
148. Yang Y., Nunes F.A., Berencsi K., Gonczol E., Engelhardt J.F., Wilson J.M. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genetics 1994, 7(3):362-369.
149. Yang Y., Su Q., Wilson J.M. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. Journal of Virology 1996, 70(10):7209-7212.
150. Yang Y., Wilson J.M. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. The Journal of Immunology 1995, 155(5):2564-2570.
151. Ye X., Lu Q., Zhao Y., Ren Z., Ren X.W., Qiu Q.H., et al. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma. International Journal of Molecular Medicine 2005, 16(6):1179-1184.
152. Zhaohui P. Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers. Human Gene Therapy 2005, 16:1016-1027.
153. Zou W., Luo C., Zhang Z., Liu J., Gu J., Pei Z., et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 2004, 23(2):457-464.